

# Petr Urbanek

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3116531/petr-urbanek-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

1,040  
citations

13  
h-index

32  
g-index

46  
ext. papers

1,197  
ext. citations

3.3  
avg, IF

3.07  
L-index

#	Paper	IF	Citations
38	Comparison of Four Bowel Cleansing Agents for Colonoscopy and the Factors Affecting their Efficacy. A Prospective, Randomized Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2021</b> , 30, 213-220	1.4	2
37	Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0244934	3.7	2
36	Cefuroxime-Associated Pancreatitis. <i>American Journal of Therapeutics</i> , <b>2020</b> ,	1	1
35	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 441-449	13.4	60
34	Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. <i>International Journal of Public Health</i> , <b>2020</b> , 65, 1723-1735	4	
33	Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. <i>Central European Journal of Public Health</i> , <b>2019</b> , 27, 93-98	1.2	3
32	Propofol-induced acute pancreatitis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2017</b> , 42, 495-498	2.2	9
31	DIABETIC KETOACIDOSIS WITH AN ACUTE ABDOMEN AS A FIRST MANIFESTATION OF TYPE 1 DIABETES MELLITUS. <i>Acta Endocrinologica</i> , <b>2017</b> , 13, 509-511	0.9	1
30	Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1112-1119	13.4	41
29	Toxic Epidermal Necrolysis After Exposure to Dithiocarbamate Fungicide Mancozeb. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 87-91	3.1	8
28	Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 3441-50	5.6	18
27	Predictive role BLVRA mRNA expression in hepatocellular cancer. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 881-887	3.1	5
26	New therapeutic options for HCV in Central Europe. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 7-11	2.2	4
25	Epidemiology of HCV infection in the Central European region. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 2-6	2.2	3
24	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138503	3.7	3
23	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 34-59	3.4	271
22	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 5-33	3.4	182

21	Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 976-83	13.4	20
20	Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 679-86	1.6	5
19	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , <b>2014</b> , 63, 1150-8	19.2	37
18	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 60-89	3.4	140
17	Chelating polymeric beads as potential therapeutics for Wilson's disease. <i>European Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 62, 1-7	5.1	8
16	Chelating polymeric particles intended for the therapy of Wilson's disease. <i>Reactive and Functional Polymers</i> , <b>2013</b> , 73, 1426-1431	4.6	7
15	806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S329-S330	13.4	3
14	Expression of Biliverdin Reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e57555	3.7	10
13	Functional variants of eNOS and iNOS genes have no relationship to the portal hypertension in patients with liver cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 592-601	2.4	2
12	Anemia as a predictor of response to antiviral therapy in chronic hepatitis C. <i>Bratislava Medical Journal</i> , <b>2013</b> , 114, 213-7	1.7	
11	12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS. <i>Journal of Hepatology</i> , <b>2012</b> , 56, S6-S7	13.4	11
10	Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. <i>Journal of Inherited Metabolic Disease</i> , <b>2012</b> , 35, 541-8	5.4	24
9	Viral hepatitis infections in chronic kidney disease patients and renal transplant recipients. <i>Kidney and Blood Pressure Research</i> , <b>2012</b> , 35, 454-67	3.1	12
8	Efficacy and safety of peginterferon $\alpha$ (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 1004-10	2.2	
7	Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. <i>Liver International</i> , <b>2011</b> , 31, 83-91	7.9	84
6	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. <i>Annals of Hepatology</i> , <b>2011</b> , 10, 445-51	3.1	4
5	Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. <i>Scandinavian Journal of Gastroenterology</i> , <b>2006</b> , 41, 1454-63	2.4	14
4	Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. <i>Blood Purification</i> , <b>2004</b> , 22, 344-50	3.1	19

3	Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , <b>2003</b> , 38, 254-9	6.9	8
2	T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C. <i>Folia Microbiologica</i> , <b>2002</b> , 47, 717-22	2.8	3
1	Production of interleukins 10 and 12 by activated peripheral blood monocytes/macrophages in patients suffering from chronic hepatitis C virus infection with respect to the response to interferon and ribavirin treatment. <i>Immunology Letters</i> , <b>2002</b> , 83, 209-14	4.1	16